Statement to mark Menstrual Hygiene Day Français
OTTAWA, ON, May 28, 2025 /CNW/ - The Honourable Rechie Valdez, Minister for Women and Gender Equality and Secretary of State (Small Business and Tourism), made the following statement on Menstrual Hygiene Day.
"Menstrual Hygiene Day is a reminder that we must always tackle the stigma around menstruation – and the very real impact that period poverty has on people's lives.
Menstrual equity also has an important impact on the economy, as period poverty can affect workforce participation, contribute to absenteeism, and limit productivity. For instance, 15% of people in Canada who menstruate say their inability to afford menstrual products holds them back from participating in daily activities, such as attending school or work. Through Food Banks Canada we are running the Menstrual Equity Fund pilot to address barriers to accessing menstrual products. This initiative is dedicated to ensuring that menstruation is never a barrier to education or employment.
This Menstrual Hygiene Day let's help raise awareness on what menstrual equity really means. Let's keep pushing to end period poverty in Canada. Join the conversation online by using #MHDay2025 and help challenge taboos and make menstrual health a priority."
Follow Women and Gender Equality Canada:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Rally in opposition to Bill No. 103 "whose primary purpose is to regulate supervised consumption sites in order to promote harmonious coexistence with the community" Français
TIOHTIA:KE, QC, MONTRÉAL, June 2, 2025 /CNW/ - On the eve of the parliamentary debates on Bill 103, the Association Québécoise pour la Promotion de la Santé des Personnes Utilisateurs de Drogues (AQPSUD) and the Association pour la Défense des Droits et l'Inclusion des personnes qui Consommation des drogues du Québec (ADDICQ) are joining forces to denounce a direct attack on the rights and health of people who use drugs. To make their demands heard, a rally will be held this Tuesday, June 3, at 2 p.m., at the Fontaine de Tourny in front of the National Assembly. While they talk, we die On May 6, 2025, Lionel Carmant, Health and Social Services Minister, introduced Bill 103. Since then, many groups have expressed their opposition to a bill that unnecessarily increases the administrative burden on organizations working in harm reduction and homelessness. Again, elected officials have chosen to talk about us, without us. Even though supervised consumption services have proven to be effective in the fight against the overdose crisis, the minister is proposing a legislative framework without any consultation, thereby jeopardizing human lives and the fragile social safety net that supports them. Bill 103 also shifts responsibility for "social co-existence" to organizations, while reinforcing the stigma of people who use drugs and those who are homeless. It reflects a chronic mistrust of community expertise and challenges its autonomy. It is time for the voices of those most affected to be heard, because it is they—we—who die when the government complicates access to services. Time is running out to destigmatize History has shown that prohibition drives people to use in isolation, which increases the risks. Too often, supervised consumption sites are the only safe spaces available. By compromising their operations, Bill 103 threatens to force many of them out of business, putting lives at risk. We are calling for the complete abandonment of this bill and a clear shift toward the decriminalization of drugs. There is an urgent need to invest heavily in affordable housing accessible to everyone and in harm reduction services, and to ensure the full inclusion of people who use drugs in the development of policies that affect them. "The perception persists that repressive approaches will overcome drug consumption or drug use. It is time to change the paradigm and come up with more appropriate solutions. " -Mario Gagnon, Chief Executive Officer of Point de Repères, at a citizens' meeting organized by L'Engrenage Saint-Roch:
Cision Canada
16 hours ago
- Cision Canada
Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025
- , June 3, 2025 /CNW/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's disease and Alpha-1 antitrypsin deficiency, announced today its participation at the GBA1 Meeting 2025, being held June 5-7, 2025 in Montreal, Canada. Congruence is also a sponsor of the meeting. "We are pleased to present our science on novel GCase activators and correctors for GBA1 Parkinson's Disease at this important scientific congress," said Sharath Hegde, Ph.D., Chief Scientific Officer of Congruence. "We are developing small molecules discovered leveraging our Revenir ™ platform that are designed to correct biological deficits resulting from mutations in the GBA1 gene. We look forward to advancing the most potent orally active and brain-penetrant allosteric GCase activator and corrector molecules for future evaluation in people living with Parkinson's disease." Oral presentation details: Title:" Discovery of Small Molecule Therapeutics for GBA1-PD" Session: 2- Small Molecules Targeting GBA1 Session Date and Time: Thursday, June 5 th, 2025, 11:40am-12:00pm Presenting Author: Indranath Ghosh, PhD, Director, Medicinal Chemistry, Congruence Therapeutics About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two recently executed multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases. For more information, please visit Media Contact Amy Conrad Juniper Point [email protected] 858-366-3243 SOURCE Congruence Therapeutics
Cision Canada
17 hours ago
- Cision Canada
National Hero John Davidson Hits the Road Once Again to Honour His Son and Push for a Cure for Duchenne Muscular Dystrophy
LONDON, ON, June 2, 2025 /CNW/ - Thirty years ago, John Davidson and his 15-year-old son Jesse captured the hearts of Canadians when John pushed Jesse across Ontario in his wheelchair to raise awareness for Duchenne muscular dystrophy. Three years later, he made the massive journey across the country. Now, approaching his 80th birthday, John is lacing up once again. On June 10, 2025, John will walk 30 kilometres from St. Thomas to London, Ontario, a symbolic route he once walked with Jesse, to commemorate 30 years since the journey that inspired the creation of Jesse's Journey (now Defeat Duchenne Canada). This special anniversary walk honours Jesse's legacy and the more than 1 in 5,000 boys affected by Duchenne, a rare and fatal genetic disorder with no cure. " When Jesse and I set out to cross Ontario in 1995, we had no idea what was ahead. But we had extreme resolve," says John. "Thirty years later, that same resolve remains solidly in place. Quitting is not an option. Everyone should try to make a difference." Since 1995, Defeat Duchenne Canada has invested nearly $19 million in 63 research projects in Canada and around the world, funding promising advancements in diagnosis, treatment, and the search for a cure. This year, the organization aims to cross a significant milestone: committing its $20 millionth dollar to Duchenne research. "What you'll see on June 10 is a dad - nearing 80 - doing his best to make a difference," John adds. "I'll be walking for Jesse, and for all the boys still waiting. I hope I see you along the road. The journey continues." Canadians across the country are invited to be part of this historic moment. Whether cheering on John along the route, donating, or sharing a message of encouragement, your support fuels hope. Learn more at About Defeat Duchenne Canada: Defeat Duchenne Canada (formerly Jesse's Journey) is the country's only national charity dedicated to ending Duchenne muscular dystrophy. Our goal is to provide leadership in research, advocacy, and support to ensure our boys can live long and active lives. About Duchenne muscular dystrophy: One in every 5,000 boys is born with Duchenne muscular dystrophy, the most common fatal form of muscular dystrophy diagnosed in children. The disease is relentless. It slowly weakens the body's muscles, deteriorating the function of vital organs and ultimately shortens their life. Although there are medical treatments that may help slow its progression, there is currently no cure and life expectancy hovers in the early thirties Social media: Facebook - @defeatduchenne Twitter - @defeatduchenne Instagram - @defeatduchenne LinkedIn - /company/defeatduchenne YouTube - /defeatduchenne SOURCE Defeat Duchenne Canada
